Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

58.81 +1.47 (+2.56%)

Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	29,064,455
Open	59.47
Bid (Size)	59.08 (900)
Ask (Size)	59.10 (600)
Prev. Close	57.34
Today's Range	58.78 - 60.64
52wk Range	43.08 - 93.80
Shares Outstanding	N/A
Dividend Yield	1.99%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Healthcare Stock Could Be One of the Best Companies to Own in 2026 ↗

Today 9:55 EST

It has strong momentum thanks to its current portfolio and several catalysts on the horizon.

Via The Motley Fool

Eli Lilly Solidifies Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences

January 09, 2026

In a move that underscores the tightening intersection between metabolic health and systemic inflammation, Eli Lilly and Company (NYSE: LLY) officially announced on January 7, 2026, its definitive...

Via MarketMinute

Performance

YTD	+12.3%	+12.3%
1 Month	+16.9%	+16.9%
3 Month	+2.3%	+2.3%
6 Month	-14.7%	-14.7%
1 Year	-31.8%	-31.8%

More News

The Great Pricing Pivot: Novo Nordisk Launches Wegovy Pill in Bid to Reclaim US Market Dominance

January 09, 2026

Via MarketMinute

Novo Nordisk Offers Oral Wegovy Pill At $149 A Month Following FDA’s Approval In December: Retail Tells Shorts ‘It’s Time To Give Up’ ↗

January 05, 2026

Via Stocktwits

The Trillion-Dollar Pharmacist: A 2026 Deep Dive into Eli Lilly (LLY)

January 09, 2026

Via PredictStreet

Nvidia’s $5 Trillion Peak Sparks Massive Nasdaq Retreat as Investors Pivot to Value

January 08, 2026

Via MarketMinute

3 of the Best Stocks Under $100 to Buy in 2026 ↗

January 08, 2026

Via The Motley Fool

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

Via MarketMinute

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

January 07, 2026

Via MarketMinute

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

January 06, 2026

Via The Motley Fool

Should Investors Be Concerned About This Pharmaceutical Giant's Latest Clinical Trial? ↗

January 06, 2026

Via The Motley Fool

The Trillion-Dollar Pivot: Eli Lilly Unleashes Volume-Led Strategy to Cement Obesity Market Dominance in 2026

January 06, 2026

Via MarketMinute

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

January 06, 2026

Via MarketMinute

The Great 2026 Pivot: Tech and Healthcare Surge as Broader Market Rally Hits a Wall

January 06, 2026

Via MarketMinute

Should You Buy Eli Lilly Before It Reaches $1 Trillion in Market Value? ↗

January 06, 2026

Via The Motley Fool

Eli Lilly Heads Toward A Defining 2026 — Can It Stay Ahead Of Novo Nordisk In The GLP-1 Showdown? ↗

January 06, 2026

Via Stocktwits

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List ↗

January 05, 2026

Via Stocktwits

Viking Therapeutics Stock Suffers Worst Day In Over 4 Months As Top Execs Dump Shares — Novo’s $149 Wegovy Move Looms ↗

January 05, 2026

Via Stocktwits

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 05, 2026

Via The Motley Fool

2 Tailwinds Behind Novo Nordisk Stock Heading Into 2026 ↗

January 03, 2026

Via The Motley Fool

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Via MarketMinute

The GLP-1 Pricing Revolution: How Novo Nordisk and Eli Lilly Redefined the Weight-Loss Market for 2026

January 02, 2026

Via MarketMinute

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

January 01, 2026

Via MarketMinute

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

Via PredictStreet

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

Via MarketMinute

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?

Yes, Novo Nordisk A/S Common Stock is publicly traded.

What exchange does Novo Nordisk A/S Common Stock trade on?

Novo Nordisk A/S Common Stock trades on the New York Stock Exchange

What is the ticker symbol for Novo Nordisk A/S Common Stock?

The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange

What is the current price of Novo Nordisk A/S Common Stock?

The current price of Novo Nordisk A/S Common Stock is 58.81

When was Novo Nordisk A/S Common Stock last traded?

The last trade of Novo Nordisk A/S Common Stock was at 01/09/26 07:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.